Brand Reference: Abilify
| Metric | Verified Benchmark | Source |
|---|---|---|
| Aripiprazole (Low-Dose Dopamine Stabilizer Adjunct) RxNorm Concept ID | 89013 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0750 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $148.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $6.40 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $8.90 / mo | 25 Zero-PHI Verified Patient Logs |
Acts as a functional dopamine-serotonin system stabilizer with ~30% intrinsic D2 partial agonist tone—boosting hypodopaminergic prefrontal motivation when paired at 2–5 mg with an SSRI while dampening mesolimbic hyperdopaminergia with minimal prolactin elevation.
CMS National Average Drug Acquisition Cost (NADAC) tracking places Aripiprazole (Low-Dose Dopamine Stabilizer Adjunct) (Abilify, RxCUI 89013) at $0.0750 per unit, whereas walk-in chain pharmacies bill cash patients an average of $148.00 monthly—creating a 96% ($141.60/mo) wholesale arbitrage spread down to $6.40.
Systemic exposure to Aripiprazole (Low-Dose Dopamine Stabilizer Adjunct) reflects 87% oral absorption kinetics and hepatic cyp2d6 and cyp3a4 dehydrogenation/hydroxylation, sustaining receptor engagement across a 75 hours parent / 94 hours active dehydro-aripiprazole half-life window (1–2 weeks adjunctive mdd remission boost response profile).
Dosing protocols (2 mg PO once daily (adjunctive MDD starter) or 5 mg PO once daily or 10 mg PO once daily) balance efficacy (81.90% patient satisfaction across 25 logs) against inner restlessness (akathisia) (21% of reports), mild weight drift (+2 kg) (13% of reports), early morning waking (12% of reports), with strict avoidance in prior neuroleptic malignant syndrome or severe akathisia intolerance.
Across 25 verified cash-pay logs, Aripiprazole (Low-Dose Dopamine Stabilizer Adjunct) achieves a 81.90% Worth-It rating with out-of-pocket spend averaging $8.90/mo versus $148.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 2 mg PO once daily (adjunctive MDD starter) for Aripiprazole (Low-Dose Dopamine Stabilizer Adjunct); monthly out-of-pocket dropped to $5.63 compared with $148.00 retail.
Completed 10 weeks on Aripiprazole (Low-Dose Dopamine Stabilizer Adjunct) (5 mg PO once daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 10 mg PO once daily Aripiprazole (Low-Dose Dopamine Stabilizer Adjunct) sourced via Local Pharmacy ($7.42/mo cash pay without insurance prior authorization).